SCHEDULE 13D/A: Baker Bros. Advisors Amends Stake in Prelude Therapeutics, Appoints New Director to Board

Baker Bros. Advisors has filed an amendment to its Schedule 13D, confirming its 23.5% beneficial ownership in Prelude Therapeutics Inc. and announcing a change in its board representation with Dr. Paul C. Scherer joining and Julian C. Baker stepping down.

Summary

• Baker Bros. Advisors LP and its affiliates (Reporting Persons) beneficially own 10,269,968 shares of Prelude Therapeutics Inc. Common Stock, representing 23.5% of the class.
• This filing is Amendment No. 4 to their Schedule 13D, updating previous disclosures.
• Dr. Paul C. Scherer, an employee of Baker Bros. Advisors, was elected to Prelude Therapeutics' Board of Directors as a Class III director, effective June 12, 2025.
• Dr. Scherer was also appointed to the Board's Compensation Committee and Governance Committee, effective June 12, 2025.
• Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC, no longer serves on the Board as he did not stand for re-election.
• The Reporting Persons hold securities for investment purposes and may purchase or dispose of additional securities based on various factors, including business prospects and market conditions.
• The beneficial ownership percentage is based on 43,610,222 shares outstanding as of April 16, 2025, plus additional shares from exercised stock options.
• Non-Voting Common Stock and Prefunded Warrants held by the Funds are subject to beneficial ownership limitations (9.99% and 4.99% respectively, with potential to increase to 19.99% after 61-day notice) and are currently not convertible/exercisable due to these limitations.
• Dr. Scherer was granted 76,000 Stock Options on June 12, 2025, exercisable at $1.04 per share, vesting over one year or until the next annual meeting.
• Julian C. Baker holds 104,644 vested Stock Options from previous board service, and Dr. Kelvin M. Neu holds 41,500 vested Stock Options from previous board service.
• The Adviser controls the voting and investment power over these stock options and any resulting common stock, with proceeds from sales remitted to the Adviser.

Sentiment

Score: 7

Explanation: The filing indicates continued strong commitment from a major institutional investor (Baker Bros. Advisors) through maintaining a significant stake and ensuring continued board representation. The strategic board change and the potential for future engagement on financing suggest active, positive involvement, despite the current limitations on converting certain securities.

Positives

• Baker Bros. Advisors, a significant institutional investor, maintains a substantial 23.5% beneficial ownership stake in Prelude Therapeutics, indicating continued confidence.
• The appointment of Dr. Paul C. Scherer, an employee of Baker Bros. Advisors, to the Board and key committees (Compensation and Governance) ensures continued representation and influence from a major shareholder.
• The transition of board representation from Julian C. Baker to Dr. Scherer suggests a strategic continuity in oversight by Baker Bros. Advisors.

Negatives

• The Non-Voting Common Stock and Prefunded Warrants held by the Funds are currently not convertible or exercisable due to beneficial ownership limitations (9.99% and 4.99% respectively), which could limit the Reporting Persons' ability to fully realize their potential stake or influence.
• While the limitations can be increased to 19.99%, this requires a 61-day notice period, introducing a delay in potential strategic actions.

Risks

• Beneficial Ownership Limitations: The Non-Voting Common Stock is not currently convertible due to a 9.99% beneficial ownership limitation, which can only be increased to 19.99% after a 61-day notice period.
• Prefunded Warrant Exercisability Limitations: The Prefunded Warrants are not currently exercisable due to a 4.99% maximum percentage limitation, which can only be increased to 19.99% after a 61-day notice period.
• Market Conditions: The Reporting Persons' future decisions to purchase or dispose of securities are subject to stock market conditions, money market conditions, and economic conditions.
• Management and Board Attitudes: Future investment decisions are influenced by the attitudes and actions of the Issuer's Board and management.

Future Outlook

The Reporting Persons may purchase additional securities or dispose of existing securities in varying amounts and at varying times, depending on their ongoing assessment of factors such as the Issuer's business prospects, other investment opportunities, economic and market conditions, and the attitudes of the Issuer's Board and management. They may also engage in discussions with the Issuer's management, other Board members, and investors, potentially including suggestions regarding financing.

Industry Context

This filing reflects a significant institutional investor's continued strategic involvement in a publicly traded biotechnology company. Baker Bros. Advisors is known for its focus on life sciences investments, and its substantial stake and board representation in Prelude Therapeutics Inc. underscore its long-term interest and potential influence in the biopharmaceutical sector. The ongoing board representation by an affiliate of a major investor is a common practice in the industry for active portfolio management.

Management Changes

Corporate Governance

Related Party Transactions

• The Adviser has voting and investment power over Common Stock, Stock Options, and Common Stock received from the exercise of Stock Options by Dr. Scherer, Julian C. Baker, and Dr. Neu, which were received as directors' compensation.
• The policy of the Funds and the Adviser does not permit managing members or full-time employees to receive compensation for serving as directors of the Issuer; instead, the Funds are entitled to the pecuniary interest in the Exercised Stock Options.
• Dr. Neu, a former employee, entered into a Nominee Agreement with the Adviser, granting the Adviser dispositive power and control over the timing of exercise of his Stock Options and requiring proceeds from sales to be remitted to the Adviser.

Stakeholder Impact

• Shareholders: The continued significant stake and board representation by Baker Bros. Advisors may be viewed positively, signaling confidence and active oversight. The limitations on conversion/exercise of certain securities might affect the perceived liquidity or full potential of the Reporting Persons' stake.
• Management/Board: The change in board representation and the potential for discussions on financing indicate ongoing engagement and influence from a major shareholder.
• Employees: No direct impact mentioned, but changes in corporate governance or strategic direction influenced by a major shareholder could indirectly affect employees.

Next Steps

• The Reporting Persons may purchase additional securities of the Issuer (via open market purchases, privately negotiated purchases, conversion of Non-Voting Common Stock, exercise of Prefunded Warrants, or exercise of Stock Options).
• The Reporting Persons may dispose of some or all of the securities of the Issuer under their control.
• The Reporting Persons may discuss items of mutual interest with the Issuer's management, other members of the Board, and other investors.
• The Reporting Persons may assess whether to make suggestions to the management of the Issuer regarding financing.
• The Funds may increase or decrease the Beneficial Ownership Limitation or Maximum Percentage applicable to their Non-Voting Common Stock and Prefunded Warrants, respectively, to any percentage not exceeding 19.99% by written notice to the Issuer, effective 61 days after delivery.

Key Dates

Recommendation

Keywords

Prelude Therapeutics Inc, Baker Bros. Advisors, Schedule 13D, Beneficial Ownership, Board of Directors, Corporate Governance, Stock Options, SEC Filing, Institutional Investor, Biotechnology, Common Stock